Ethereum plans to increase its gas limit from around 60 million to 200 million after the upcoming Glamsterdam upgrade, significantly expanding its capacity to process transactions and smart contracts. This ambitious step, supported by new projects like ePBS, Block-Level Access Lists, and EIP-8037, aims to improve throughput without compromising network stability by adjusting gas prices for costly operations. The upgrade will first be tested on the Sepolia testnet on October 6, 2026, before a mainnet rollout, marking a major milestone in Ethereum's ongoing scalability improvements.
Ethereum's planned increase of its gas limit to 200 million marks a significant scalability milestone. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 02, 2026 02:41 WIB: out of 50 major cryptocurrencies, 30 rose and 19 fell today. Notable movers include SUSHI at Rp4.710 with a 3.14% decline and a typical hold time of 101 days, THETA at Rp3.930 down 3.06% with 69% buy order activity, and LTC at Rp1.214.867 up 2.71% with a typical hold time of 78 days.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
